Greenwich LifeSciences (GLSI) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Greenwich LifeSciences (GLSI) over the past year, gaining 62.9% versus a gain of 32.3%. Over five years, GLSI leads with a -60.1% price change compared with -87.2% for WHWK. Greenwich LifeSciences is the larger company by market cap ($222.2 million vs $197.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GLSI | WHWK |
|---|---|---|
| Share price | $15.14 | $3.47 |
| Market cap | $222.23M | $197.82M |
| 1-day change | -1.62% | +1.76% |
| YTD return | -27.94% | +43.39% |
| 1-year return | +32.28% | +62.91% |
| 5-year return | -60.12% | -87.25% |
| EPS (TTM) | $-1.53 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $34.10 | $5.50 |
| 52-week low | $7.78 | $1.87 |
| Distance from 52-week high | -55.60% | -36.85% |
| Analyst consensus | none | buy |
| Avg. price target upside | +276.49% | +122.19% |
| Average volume | 138.91K | 367.72K |
| Shares outstanding | 14.68M | 57.01M |
| Employees | — | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed GLSI by 30.6 percentage points over the past year.
About Greenwich LifeSciences
GLSI stock →Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers in the United States. Its lead product candidate is GP2, a HER2/neu transmembrane peptide, which is in Phase III clinical trial to prevent breast cancer recurrences in patients.
Health Care · Biotechnology: Pharmaceutical Preparations
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
GLSI vs WHWK FAQ
Which is bigger, Greenwich LifeSciences or Whitehawk Therapeutics?
Greenwich LifeSciences (GLSI) is larger, with a market capitalization of $222.23M compared with $197.82M for Whitehawk Therapeutics (WHWK).
Which stock has performed better over the past year, GLSI or WHWK?
WHWK returned +62.91% over the past 12 months, compared with +32.28% for GLSI (price return, excluding dividends). Past performance does not predict future results.
Are Greenwich LifeSciences and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.